Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
16P11.2 Deletion Syndrome: early-phase trial registry
1 of 2 indexed 16P11.2 Deletion Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
16P11.2 Deletion Syndrome: 2 US clinical trials tracked, 1 recruiting.
16P11.2 Deletion Syndrome is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Clinical Research Associates, running 1 of these trials.
Enrollment posture brief
Registry condition 16p112-deletion-syndrome
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
16P11.2 Deletion Syndrome lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for 16P11.2 Deletion Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
16P11.2 Deletion Syndrome is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight
Simons Searchlight
NCT01238250
Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion
Clinical Research Associates
NCT04271332
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on 16P11.2 Deletion Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on 16P11.2 Deletion Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this 16P11.2 Deletion Syndrome page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 16P11.2 Deletion Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Clinical Research Associates sponsors the most 16P11.2 Deletion Syndrome trials on record, review their full trial history before evaluating a specific study. See Clinical Research Associates's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This 16P11.2 Deletion Syndrome condition card totals 2 registered trials; most-linked intervention Arbaclofen; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.